The incidence of inflammatory bowel diseases (IBD) - Crohn’s disease (CD) and ulcerative colitis (UC) - has been increasing on a global scale, and progressively, more gastroenterologists will be included in the diagnosis and treatment of IBD. Although IBD primarily affects the intestinal tract, extraintestinal manifestations of the disease are often apparent, including in the oral cavity, especially in CD.
Specific oral manifestations in patients with CD are as follows: indurate mucosal tags, cobblestoning and mucogingivitis, deep linear ulcerations and lip swelling with vertical fissures. The most common non-specific manifestations, such as aphthous stomatitis and angular cheilitis, occur in both diseases, while pyostomatitis vegetans is more pronounced in patients with UC. Non-specific lesions in the oral cavity can also be the result of malnutrition and drugs.
Malnutrition, followed by anemia and mineral and vitamin deficiency, affects the oral cavity and teeth. Furthermore, all of the drug classes that are applied to the treatment of inflammatory bowel diseases can lead to alterations in the oral cavity due to the direct toxic effects of the drugs on oral tissues, as well as indirect immunosuppressive effects with a risk of developing opportunistic infections or bone marrow suppression. There is a higher occurrence of malignant diseases in patients with IBD, which is related to the disease itself and to the IBD-related therapy with a possible oral pathology.
Treatment of oral lesions includes treatment of the alterations in the oral cavity according to the etiology together with treatment of the primary intestinal disease, which requires adequate knowledge and a strong cooperation between gastroenterologists and specialists in oral medicine.
Authors: Miranda Muhvić-Urek, Marija Tomac-Stojmenović, Brankica Mijandrušić-Sinčić
Source: https://pmc.ncbi.nlm.nih.gov/
Oral pathology 06 July 2026
This peer-reviewed oral pathology article summarizes clinical evidence from Oral oncology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 02 July 2026
This peer-reviewed oral pathology article summarizes clinical evidence from BMC oral health (2024). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 29 June 2026
This peer-reviewed oral pathology article summarizes clinical evidence from Oral oncology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 19 June 2026
This peer-reviewed oral pathology article summarizes clinical evidence from BMC oral health (2024). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Oral pathology 15 June 2026
This peer-reviewed oral pathology article summarizes clinical evidence from Oral oncology (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient...
Aligners F22® is an Edra professional dentistry reference focused on clinical practice, education and treatment planning.
Products 10 July 2026
Planmeca introduces two dental units designed to support modern clinical workflows through different concepts and use cases.
News 10 July 2026
BIOLASE, a MegaGen company and global leader in dental laser technology, today announced a significant investment in its Corona, California, manufacturing operations, underscoring
News 10 July 2026
Led by Farhad Boltchi, DMD, and Darin Dichter, DMD, the program provides a real-time look at the clinical decisions that shape anterior implant outcomes
Editorials 10 July 2026
From California to Canada: CU Anschutz School of Dental Medicine at ADEA, GRC and IADR 2026
The CU Anschutz School of Dental Medicine will showcase a wide breadth of educational innovation, faculty development, clinical training and research at three major gatherings this